Document:

Exhibit 10.9

[CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT AND FILED SEPARATELY
WITH THE SEC PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24b-2.]

                                LICENSE AGREEMENT

        THIS AGREEMENT is made and effective as of this 10th day of November,
1997 by and between CNS, Inc., a Delaware corporation ("Licensee"), and Onesta
Nutrition, Inc., a Minnesota corporation ("Licensor").

                                    RECITALS

        WHEREAS, Licensor is now and has been engaged in developing certain
Products (as defined in Subsection 1.1) for use in providing dietary fiber in
tablet form.

        WHEREAS, the Products embody inventions and designs owned exclusively by
Licensor and Licensor has available certain Know-how relating to the manufacture
of the Products;

        WHEREAS, Licensor owns or controls, or may hereafter own or control,
certain Know-how, patents or patent applications relating to the Products;

        WHEREAS, Licensee desires to obtain an exclusive worldwide license from
Licensor of certain Know-how, patents and patent applications of Licensor
relating to the manufacture and use of the Products for providing dietary fiber
and Licensor is willing to grant such a license to Licensee.

        NOW, THEREFORE, in consideration of the premises, the mutual covenants
and agreements hereinafter set forth and other good consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties agree as follows:

        1. GENERAL DEFINITIONS. As used herein, the following terms shall be
defined in the manner set forth below:

                1.1 Products. The term "Products" shall mean the soluble fiber
supplement product described on Schedule 1.1 attached hereto, the manufacture,
use or sale of which is covered by the Licensed Patents or is made or developed
through the use of the Know-How, including all improvements thereto, and any
other inulin-based soluble fiber supplement products developed by Licensor or
any of its employees, consultants, agents or representatives during the term of
this Agreement using any Licensed Patents or Know-how; provided, however, that
for any such improvement or enhancement or similar product developed by Licensor
to be included within the license herein granted, Licensor shall notify Licensee
of any such improvement or enhancement and Licensee shall at its option make an
election to include such improvement or enhancement in this License by providing
written notice of such election to Licensor within thirty (30) days after
Licensee learns of such improvement, enhancement or similar product. If Licensee
shall make an such election, Licensee shall reimburse Licensor for reasonable
expenses incurred in developing such improvement or enhancement or similar
product.

                1.2 Know-how. The term "Know-how" shall mean any and all
tangible and intangible information, technology, documents and materials in the
possession and control of Licensor, and necessary in order to enable Licensee to
utilize fully the rights granted by Licensor to Licensee hereunder and shall
include, without limiting the foregoing, the ideas, concepts, confidential
information, trade secrets and techniques, as well as all the materials,
documents, manuals, specifications, patterns, art work, bills of materials and
other information of Licensor relating to the Products.

<PAGE>

                1.3 Licensed Patents. The term "Licensed Patents" shall mean the
following: (i) the United States and foreign patent(s) and patent application(s)
to the Products listed on Schedule 1.3 attached hereto; (ii) all future United
States or foreign patent applications related to the Products and any patents
arising therefrom; (iii) the rights, patents and patent applications, if any, in
any country or jurisdiction in the world corresponding to the United States
patent applications; and (iv) any division, continuation, continuation-in-part,
divisional, re-examined, reissued or extended letters patent, applications and
petty patents, utility models, utility model conversions, inventor's
certificates relating to the inventions claimed in any of the foregoing United
States patents and patents pending and foreign patent rights, which may be
developed, acquired or controlled by Licensor during the term of this Agreement
and with respect to which Licensor shall have the right to grant the license
hereinafter provided.

                1.4. Contract Year and Quarter. The term "Contract Year" shall
mean each period following October 1 of 1998, 1999 and 2000. The term "Contract
Quarter" shall mean each period of three consecutive months commencing January
1, April 1, July 1 and October 1.

                1.5. Gross Revenues. The term "Gross Revenues" shall mean the
gross amounts collected by Licensee from any end-user, sublicensee, assignee or
other person or entity relating to or arising from the sale of Products after
the deduction of (i) any amounts repaid or credited by reason of rejections or
returns, and (ii) trade and quantity discounts actually allowed and taken.

                1.6. Earned Royalty . The term "Earned Royalty" shall mean the
royalty payable to Licensor on Products.

        2. GRANT OF LICENSES.

                2.1 Patent and Know-how License. Licensor hereby grants to
Licensee a sole and exclusive, worldwide, transferable right and license under
the Licensed Patents and Know-How to make, have made, use, import, offer for
sale and sell the Products and to practice worldwide any process claimed or
disclosed in the Licensed Patents and Know-how. Without limiting the foregoing,
the Licensed Products may be distributed as a product to consumers, retailers,
wholesalers or otherwise.

                2.2 Sublicenses and Assignments. Licensee may sublicense and/or
assign to any third party, including affiliates of Licensee, any and all rights
granted hereunder. In the event of an assignment, Licensee shall enter into a
written agreement with the assignee pursuant to which the assignee shall assume
all of the obligations of Licensee under this Agreement and this Agreement shall
be binding upon and inure to the benefit of such assignee. In the event of a
sub-license, Licensee shall enter into a written agreement with sub-licensee (i)
with a term no greater than the term of this Agreement, (ii) with rights granted
to sub- licensee which are no greater than the terms of this Agreement, and
(iii) pursuant to which Licensee shall use reasonable business efforts to impose
upon sub-licensees similar obligations as Licensor has imposed upon Licensee
under this Agreement.

                2.3 Patent Procurement and Costs. Licensee shall be responsible
for and pay all patent costs and expenses (including reasonable attorneys' fees)
incurred by Licensor in obtaining, prosecuting, owning and maintaining any of
the Licensed Patents issued or to be issued under the law of any country or
jurisdiction, including filing, prosecution, working and maintenance costs and
taxes. Licensee shall have the right to review and comment on Licensor's filings
with respect to the Licensed Patents, at Licensee's own expense. Notwithstanding
the above, Licensor shall direct and control the procurement of the Licensed
Patents using patent counsel of its own choosing for such procurement (the
choice and which counsel is subject to the reasonable consent of Licensee). Such
patent costs and expenses incurred by Licensor and reimbursed by Licensee
hereunder may be offset against the royalties payable under excess of running
royalties payable under Section 4.1 over the minimum royalties payable under
Section 4.3 in any Contract Quarter to the extent that such excess arises from
sales of Licensed Products in the country or region in which such patent costs
and expenses were incurred.

<PAGE>

                2.4 Exploitation. Licensee hereby agrees that during the term of
this Agreement it will use its reasonable best efforts to manufacture, sell and
market the Products, and will exert its reasonable best efforts to create a
demand for the Products worldwide, and to increase and extend its business in
the manufacture, sale and marketing of the Products worldwide.

        3. REPRESENTATIONS AND WARRANTIES.

                3.1 Licensor hereby warrants and represents to Licensee as
follows:

                (a) Licensor is a corporation duly organized, validly existing
        and in good standing under the laws of the State of Minnesota.

                (b) This Agreement has been duly authorized, executed and
        delivered by Licensor and constitutes a valid and binding obligation of
        Licensor, enforceable in accordance with its terms, except as rights to
        indemnification thereunder may be limited by applicable law and except
        as the enforcement thereof may be limited by bankruptcy, insolvency,
        reorganization, moratorium or other similar laws relating to or
        affecting creditors' rights generally or by general equitable
        principles. The execution, delivery and performance of this Agreement by
        Licensor and the consummation of the transactions contemplated hereby do
        not and will not conflict with or result in any material breach of any
        of the provisions of, or constitute a material default under, or result
        in a material violation of, or require any authorization, consent or
        approval, under the provisions of such party's Articles of Incorporation
        or Bylaws or any other agreement or instrument to which such party is
        bound or affected, or to he best of Licensor's knowledge, any law,
        statute, rule, regulation, judgment order or decree to which such party
        is subject.

                (c) Licensor owns all the rights of Jerome J. Licari, Ph-D and
        all other employees, agents, consultants or representatives of Licensor
        with respect to the Products, Licensed Patents and Know-how.

                (d) Licensor has filed the patent applications listed on
        Schedule 1.3.

                (e) To Licensor's knowledge, the Products, Licensed Patents and
        Know-how do not infringe on any patent, copyright or other intellectual
        property right of any third party.

                (f) Licensor has not received notice of any claims, actions,
        suits or proceedings pending or threatened effecting Licensor, the
        Licensed Patents or Know-how which, if adversely determined, would have
        a material adverse effect upon Licensee's ability to manufacture, have
        manufactured, use or sell the Products or otherwise practice the rights
        and technology licensed to Licensee by Licensor under this Agreement
        and, to the best of Licensor's knowledge, there is no reasonable basis
        for anyone to bring such claims, actions, suits or proceedings.

                (g) Licensor has not received any claim from any third-party
        proceedings relating to the Licensed Patents, Know-how, or the Products
        which are based upon infringement of any patent or misappropriation or
        misuse of trade secrets.

                (h) Licensor represents that the product, in its current form,
        is manufacturable in quantities sufficient enough to meet the sales
        levels required for the minimum guaranteed royalties.

                (i) That certain License Agreement between Licensor and Johnson
        & Johnson/Merck Consumer Pharmaceuticals Company ("JJMCP"), dated March
        31, 1997, was terminated effective June 25, 1997, and Licensor retains a
        royalty-free unrestricted right to use any information concerning the
        manufacture, formulation and use of the Licensed Products not generally
        known to the public, and developed by JJMCP during the term of such
        agreement (other than information covered by any published patent or
        patent application).

<PAGE>

                3.2 Licensee hereby warrants and represents to Licensor as
follows:

                (a) Licensee is a corporation duly organized, validly existing
        and in good standing under the laws of the State of Delaware.

                (b) This Agreement has been duly authorized, executed and
        delivered by Licensee and constitutes a valid and binding obligation of
        Licensee, enforceable in accordance with its terms, except as rights to
        indemnification thereunder may be limited by applicable law and except
        as the enforcement thereof may be limited by bankruptcy, insolvency,
        reorganization, moratorium or other similar laws relating to or
        affecting creditors' rights generally or by general equitable
        principles. The execution, delivery and performance of this Agreement by
        Licensee and the consummation of the transactions contemplated hereby do
        not and will not conflict with or result in any material breach of any
        of the provisions of, or constitute a material default under, or result
        in a material violation of, or require any authorization consent or
        approval, under the provisions of Licensee's Certificate of
        Incorporation or Bylaws or, to the best of Licensee's knowledge, any
        other agreement or instrument to which such party is bound or affected,
        or any law, statute, rule, regulation, judgment order or decree to which
        such party is subject.

        4. CONSIDERATION AND REPORTS.

                4.1 Royalties. Licensee agrees to pay to Licensor royalties as
follows based on the Gross Revenues from the sale of Products: (a) [CONFIDENTIAL
TREATMENT REQUESTED]% of Gross Revenues until royalties have been paid on an
aggregate total of $[CONFIDENTIAL TREATMENT REQUESTED] of Gross Revenues, then
(b) [CONFIDENTIAL TREATMENT REQUESTED]% of Gross Revenues until royalties have
been paid on an aggregate total of $[CONFIDENTIAL TREATMENT REQUESTED] of Gross
Revenues, and then (c) [CONFIDENTIAL TREATMENT REQUESTED]% of all Gross Revenues
in excess of an aggregate total of $[CONFIDENTIAL TREATMENT REQUESTED]. The
royalty provided for in this Subsection 4.1 shall be reduced to [CONFIDENTIAL
TREATMENT REQUESTED]% of the otherwise applicable rate, on a country-by-country
basis if no Licensed Patent issues in such country.

                4.2 Quarterly Payments. All royalties due Licensor from Licensee
hereunder shall be payable on a Contract Quarterly basis. Within forty-five (45)
days after the end of each Contract Quarter during the term of this Agreement,
Licensee shall pay to Licensor, by wire transfer to an account designated
pursuant to Section 10.4, the royalty due Licensor under Subsection 4.1 through
the end of the preceding Contract Quarter and shall furnish Licensor with a
written statement setting forth the number of Products sold and the Gross
Revenues received during such Contract Quarter, and the resulting amount of the
royalty due Licensor under Subsection 4.1.

                4.3 Minimum Royalties.

                (a) To maintain its rights hereunder, Licensee shall pay to
        Licensor minimum royalties as follows in the event that the Products may
        be marketed and sold without a prescription:

<TABLE>
<CAPTION>
                      Minimum Royalty Payment               Minimum Royalty Payment
Contract Year*         Per Contract Year per                   Contract Quarter
--------------        -----------------------               -----------------------
<S>             <C>                                   <C>
Year 1          $[CONFIDENTIAL TREATMENT REQUESTED]   $[CONFIDENTIAL TREATMENT REQUESTED]
Year 2           [CONFIDENTIAL TREATMENT REQUESTED]    [CONFIDENTIAL TREATMENT REQUESTED]
Year 3**         [CONFIDENTIAL TREATMENT REQUESTED]    [CONFIDENTIAL TREATMENT REQUESTED]
</TABLE>

*       Twelve-month periods beginning on the Contract Year.
**      Through the Contract Year of the expiration date of the last of the
        Licensed Patents or if no Licensed Patent issues, December 26, 2015.

<PAGE>

                (b) In the event the royalty is reduced pursuant to Subsection
        4.1 above, the minimum royalties provided for in Subsection 4.3(a) shall
        be reduced by [CONFIDENTIAL TREATMENT REQUESTED] in each Contract Year,
        pro rata on a country-by-country basis.

                4.4 Minimum Royalty Payment. Licensee shall pay Licensor within
forty-five (45) days after the end of each Contract Quarter, by wire transfer to
an account designated pursuant to Section 10.4, an amount equal to the minimum
royalties payable pursuant to the terms of Subsection 4.3 for the Contract
Quarter then ended, less: (a) the aggregate amount of Earned Royalties actually
paid to Licensor pursuant to the terms of Subsections 4.1 and 4.2 for the
Contract Quarter then ended; and (b) any Earned Royalties paid to Licensor
during the prior Contract Quarters in the current Contract Year that exceed the
amount of cumulative minimum royalties payable for those Contract Quarters;
provided that in no event shall such deductions reduce the payment to Licensor
in any Contract Year below the then applicable minimum annual royalty payable
under 4.3 of this Agreement. Licensee's failure to pay any and all amounts
payable under the preceding sentence within thirty (30) days after receipt of
written notice from Licensor that such amounts have not been timely paid shall
render the licenses granted hereunder void and thereupon, Licensee shall have no
further rights or interests of any kind or nature with respect to the Products,
Know-how, License or Patents and Licensee shall take any and all action that
Licensor may request to further document the provisions hereof. In the event
that any law, statute, regulation, rule, guideline, ruling or decision of any
governmental or regulatory agency prevents Licensee from marketing or offering
Products for sale, the minimum royalty payment will be suspended until such time
that Licensee is no longer prevented from marketing or offering Products for
sale, such suspension to be determined pro rata on a country-by-country basis.

                4.5 Late Payment. Licensee shall have ten (10) days to make any
late payments hereunder, without interest. Thereafter, Licensee shall pay a late
payment fee to Licensor calculated at a variable rate of 2% over the prime per
annum interest rate as set from time to time by Norwest Bank Minneapolis, N.A. ,
Minneapolis, Minnesota (the "Interest Rate"), on any and all amounts that are at
any time overdue and payable to Licensor under this Agreement, such interest
being calculated on each such overdue amount from the date when such amount
became due to the date of actual payment thereof. Such late payment fee shall be
in addition to and not in lieu of any and all other rights or remedies that
Licensor may have under this Agreement or law relating to a default by Licensee
under this Agreement.

                4.6 Records. During the term of this Agreement and for three (3)
years after termination of this Agreement, Licensee shall at all times maintain
accurate and up-to-date records containing complete data from which amounts due
to Licensor under this Agreement may be readily calculated. Further, Licensee
shall preserve and permit examination of such records by Licensor's
representatives at reasonable intervals and under reasonable conditions during
the term of this Agreement and for three (3) years thereafter and, upon request,
shall supply to Licensor's representatives all information useful in making a
proper audit and verification of Licensee's performance of its obligations under
this Agreement.

                4.7 Underpayment. If Licensor determines by audit and inspection
of Licensee's books and records that Licensee has failed to pay all royalties
due under Subsection 4.1, Licensee shall pay Licensor 105% of such additional
royalties as may be due, plus interest thereon. If the amount of underpayment
exceeds 5% of the royalties due under Subsection 4.1, then Licensor shall, in
addition to any other remedies available to it, recover from Licensee the
reasonable costs incurred in making any such audit and inspection pursuant to
Subsection 4.6 hereof which revealed such shortfall and Licensee shall pay
Licensor 105% of such additional royalties, plus interest thereon.

        5. INDEMNIFICATION.

                5.1 Indemnification by Licensor. Licensor shall indemnify and
hold Licensee harmless from and against any and all claims, damages, costs
(including reasonable attorneys' fees), judgments and liabilities of any kind or
nature arising out of any third party claim of (a) any breach by Licensor of any
of its warranties, representations and covenants under this Agreement or (b) any
misuse by Licensor of the patent process or fraud by Licensor on the patent
office or notice by Licensor before the date hereof of a claim by any party of a
prior or superseding right to practice the art of and commercialize the
Products.

<PAGE>

                5.2 Indemnification by Licensee. Licensee shall indemnify and
hold Licensor harmless from and against any and all claims, damages, costs
(including reasonable attorneys'.fees), judgments -and liabilities of any kind
or nature: (a) arising out of any third party claim of the breach by Licensee of
any of its warranties, representations and covenants under this Agreement; or
(b) arising out of any actual or alleged defect in a Product.

        6. PROTECTION AGAINST INFRINGEMENT. In the event that Licensee becomes
aware of activity on the part of any third party which may constitute
infringement of the Licensed Patents, or any other intellectual property rights
with respect to which Licensee is granted a license hereunder, Licensee shall
give Licensor written notice thereof. Upon reasonable request by Licensor,
Licensee shall, at its sole expense, initiate and thereafter diligently maintain
reasonable efforts to prevent and abate such infringement, including the
initiation of an appropriate civil action for infringement and the taking of
such other action as may be necessary or appropriate, to enforce the Licensed
Patents or other intellectual property rights with respect to -which Licensee is
granted a license hereunder. In such event, (i) Licensor will permit the use of
its name in, and as a party to, all such suits and execute all pleadings,
documents and other papers necessary or appropriate in conjunction therewith and
(ii) Licensee shall receive the full benefits of any action it takes pursuant to
this subsection, including retaining all sums recovered in any such suit or in
settlement thereof after paying Licensor the Earned Royalties which shall be
calculated from the amount of Gross Revenues, if any, asserted by Licensee to
support any award of compensatory damages (as opposed to punitive or any other
damages). Licensor may, at its option and its cost and expense, participate in
meetings with Licensee and/or its counsel and receive all pleadings, documents
and other related papers useful for the purpose of keeping Licensor informed of
the status of any proceedings commenced by Licensee pursuant to this Section 6.

        7. TERM AND TERMINATION.

                7.1 Term. This Agreement shall commence on the effective date
hereof and shall expire, unless earlier terminated pursuant to Subsections 4.8,
7.2 or 7.3 of this Agreement, upon the later of (a) the expiration of the last
of the Licensed Patents to expire or (b) December 26, 2015.

                7.2 Termination by Licensor. If Licensee defaults in any of its
obligations under this Agreement, Licensor shall have the right to terminate
this Agreement by giving thirty (30) days' written notice of termination
specifying the reason for termination, provided that such notice will be of no
effect and termination will not occur if the specified default is cured prior to
the expiration of said thirty (30) day notice period.

                7.3 Termination by Licensee. (a) This Agreement may be
terminated by Licensee at any time at will, with or without cause, by the giving
of at least ninety (90) days' written notice to Licensor by Licensee, in which
event such license shall terminate upon the effective date stated in any such
notice. In the event of the termination of any such license, neither Licensor
nor Licensee shall have any further obligation to the other party hereunder
except as expressly provided in Sections 7.4 and 8.1 below.

                (b) Upon the termination of any license granted under this
        Agreement, Licensee may, after the effective date of such termination,
        sell any of its (i) completed Products, (ii) Products then in the
        process of manufacture and (iii) Products with respect to which
        manufacture has been committed at the time of termination by reason of
        either (x) any contracts for the purchase of materials to be used in the
        manufacture of such Products or (y) any contract for the sale of such
        Products. All such sales and uses shall be subject to the royalty
        provisions of Section 4 of this Agreement as though the termination of
        this Agreement had not occurred.

<PAGE>

                (c) Except as expressly provided in Subsection 7.3(b), after
        termination of this Agreement, Licensee may not use develop, market or
        sell the Products, Know-how, or Licensed Patents in any way or manner
        that would violate any rights of Licensor and all rights with respect to
        the Licensed Products, Know-how or Licensed Patents shall revert to
        Licensor. In addition, Licensee shall assign to Licensor, and hereby
        does, effective only upon such termination, any and all (i) improvements
        to the Licensed Products, Know-how or Licensed Patents conceived or
        reduced to practice during the term of this Agreement and (ii)
        trademarks for the Licensed Products (other than master brand trademarks
        of Licensee which shall be retained by Licensee). Licensee shall take
        any and all steps reasonably requested by Licensor to fully document the
        complete vesting of such rights in Licensor upon any such termination.

                7.4 Continued Obligations. Termination shall not relieve or
release either party from its obligations to make any payment which may be owing
to the other under the terms of this Agreement or from any other liability which
either party may have to the other arising out of the terms of this Agreement.
Additionally, notwithstanding anything contained herein to the contrary,
Sections 3, 4 (including Subsection 4.8 to the extent then exercised), 5 and 8.2
shall survive termination of this Agreement and remain in full force and effect;
provided, that Licensor and Licensee hereby acknowledge that they may not bring
claims against one another based upon the representations and warranties
contained in Section 3, except to the extent such representations and warranties
are not accurate as of the date hereof.

        8. LICENSEE'S UNDERTAKINGS.

                8.1 Licensing Fee and Payment. Licensee will pay to Licensor the
sum of $[CONFIDENTIAL TREATMENT REQUESTED] as a license fee. The license fee
will be payable to, Licensee, by wire transfer to an account designated pursuant
to Section 10.4, as follows:

                (a) $[CONFIDENTIAL TREATMENT REQUESTED] at the time of execution
        of this License Agreement.

                (b) $[CONFIDENTIAL TREATMENT REQUESTED] at the beginning of each
        of the next three calendar quarters. If this Agreement is terminated by
        Licensee prior to the payment of all license fees under this Section
        8.1, the remaining payments shall be paid on or before the effective
        date of such termination. All license fees shall be non-refundable. Of
        the total $[CONFIDENTIAL TREATMENT REQUESTED] license fee,
        $[CONFIDENTIAL TREATMENT REQUESTED] shall be set off against and reduce
        the royalty payments to be made to Licensor under Section 4 of this
        Agreement. Such credit shall be applied at the rate of [CONFIDENTIAL
        TREATMENT REQUESTED] percent ([CONFIDENTIAL TREATMENT REQUESTED]%) of
        the excess of running royalties payable under Section 4.1 over the
        minimum royalties payable under Section 4.3 in any Contract Quarter.

                8.2 Confidentiality. Licensee shall maintain the confidentiality
of Licensor's confidential information, both during and after the term of this
Agreement. After this Agreement is terminated, Licensee shall not use any of
Licensor's confidential information for any purpose that is not specifically
provided for in Subsection 7.3(b) of this Agreement.

                8.3 Press Release. Upon launch of the first Licensed Product,
Licensee shall issue a press release, reasonably satisfactory to Licensor, which
shall, in part, acknowledge Onesta's and/or Licari's role in developing the
Licensed Products.

        9. LICENSOR'S UNDERTAKINGS.

                9.1 Disclosure of Improvements. Licensor agrees to promptly
disclose to Licensee any improvement, enhancement or modification to the
Products that Licensor may develop during the term of this Agreement or any
other inulin-based soluble fiber supplement products.

<PAGE>

        10. MISCELLANEOUS.

                10.1 Force majeure. Neither party shall be responsible for any
delay or failure in the performance of any obligation hereunder due to strikes,
lockouts, fires, floods, acts of God, embargoes, wars, riots, or act or order of
any government or governmental agency; provided, however, nothing set forth in
this Subsection 10.1 shall be construed to relieve Licensee of the requirement
that it pay minimum royalties pursuant to Subsections 4.3 and 4.4 hereof.

                10.2 Waiver. The waiver or failure of either party to enforce
the terms of this Agreement in one instance shall not constitute a waiver of
said party's right under this Agreement with respect to other violations.

                10.3 Remedies. The election by either party of any particular
right or remedy shall not be deemed to exclude any other right or remedy and all
rights and remedies of either party shall be cumulative. The parties agree that,
in addition to any other relief afforded under the terms of this Agreement or by
law, each party shall have the right to enforce this Agreement by injunctive or
mandatory relief to be issued against the other party, it being understood that
both damages and specific performance shall be proper modes of relief and are
not to be considered as alternative remedies.

                10.4 Notices. All notices and replies thereto required hereunder
shall be in writing, signed by the party giving notice, placed in an envelope
and either delivered by hand or sent by facsimile or registered mail, postage
prepaid, return receipt requested, and properly addressed to the other party.
Notices sent by mail shall be deemed received on the date of receipt indicated
by the receipt verification provided by the United States Postal Service.
Notices sent by facsimile shall be deemed received on the date indicated on the
sender's confirmation report. Notice shall be given, mailed or sent to the other
party at the following addresses or at such other address as may be given by
proper notice:

                If to Licensor:      Onesta Nutrition, Inc.
                                     [CONFIDENTIAL TREATMENT REQUESTED]
                                     [CONFIDENTIAL TREATMENT REQUESTED]
                                     Attn: Jerome J. Licari, Ph.D
                                     Fax No.: [CONFIDENTIAL TREATMENT REQUESTED]

                Wire transfer
                information:         Anchor Bank of Wayzata
                                     1055 Wayzata Boulevard
                                     Wayzata, MN 55391
                                     ABA Routing No: [CONFIDENTIAL TREATMENT
                                                      REQUESTED]
                                     Account No: [CONFIDENTIAL TREATMENT
                                                  REQUESTED]

                With a copy to:      Dorsey & Whitney LLP
                                     220 South Sixth Street
                                     Minneapolis, MN 55402-1498
                                     Attn: Karin A. Keitel
                                     Fax No.: 612-340-8827

                If to Licensee:      CNS, Inc.
                                     4400 West 78th Street
                                     Minneapolis, MN 55435
                                     Attn: Daniel E. Cohen, M.D.
                                     Fax No.: 612-820-6697

<PAGE>

                With a copy to:      Lindquist & Vennum P.L.L.P.
                                     4200 IDS Center
                                     80 South 8th Street
                                     Minneapolis, MN 55402-2205
                                     Attn: Patrick Delaney
                                     Fax No.: 612-371-3207

Either party hereto may designate any other address for notices or account for
wire transfer given hereunder by written notice to the other party given at
least ten (10) days prior to the effective date of such change.

                10.5 Entire Agreement. This Agreement represents the entire
agreement between the parties with respect to the subject matter hereof; there
are no oral promises, representations or warranties. No modification of this
Agreement or waiver of any of its terms shall be binding upon the parties unless
said modification or waiver is in writing, signed by both parties, and states
that it is an amendment to this Agreement.

                10.6 Parties in Interest. This Agreement shall inure to the
benefit of, be binding upon, and be enforceable against the parties hereto,
their respective successors and assigns.

                10.7 Governing Law. This Agreement shall be governed by,
construed and enforced under the internal laws (and not the laws of conflicts)
of the State of Minnesota. Licensee irrevocably submits to the jurisdiction of
the Minnesota state courts and federal courts sitting in Minneapolis or St.
Paul, Minnesota in connection with any action or proceeding arising out of or
relating to this Agreement and agrees that all claims in respect of such action
or proceeding shall be heard and determined in any such court.

                10.8 Severability. If any portion of this Agreement is held
invalid by the final judgment of any court of competent jurisdiction, such
portion shall be deemed revised or "blue lined" so that it is enforceable to the
fullest extent possible under applicable law and the remaining provisions shall
remain in full force and effect as if such invalid provision had not been
included herein.

        IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.

                                       CNS, INC.

                                       By
                                          --------------------------------------
                                         Its:
                                              ----------------------------------

                                       ONESTA NUTRITION, INC.

                                       By
                                          --------------------------------------
                                         Its:
                                              ----------------------------------

<PAGE>

                                LIST OF SCHEDULES

                   Number                            Description
                   ------                            -----------

                     1.1                             Products

                     1.3                             Licensed Patents

<PAGE>

                                  SCHEDULE 1.1

                             DESCRIPTION OF PRODUCTS

        Soluble fiber supplement product covered by the Licensed Patents or made
or developed through the use of Know-How.

<PAGE>

                                  SCHEDULE 1.3

                         DESCRIPTION OF LICENSED PATENTS

U.S. Patent Application Serial No. 60/009,231 filed December 26, 1995, "Dietary
         Fiber Delivery System"

U.S. Patent Application Serial No. 08/771,960 filed December 23, 1995, "Dietary
         Fiber Delivery System"

PCT Patent Application PCT/US 96/20245 filed December 23, 1996, "Dietary Fiber
         Delivery System"Exhibit 10.10

[CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT AND FILED SEPARATELY
WITH THE SEC PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24b-2.]

                                LICENSE AGREEMENT

         THIS AGREEMENT (the "Agreement") is made and effective as of this 12th
day of March, 1999 by and between CNS, Inc., a Delaware corporation
("Licensee"), and WinEase, L.L.C., a Minnesota limited liability company
("Licensor").

                                    RECITALS

         WHEREAS, Licensor is now and has been engaged in developing certain
technology related to animal care and specifically has developed products and
methods directed to the support of nasal passages for animals, including the
"Products" (as defined in Paragraph 1.1 below);

         WHEREAS, Licensor owns certain patents, pending patent applications and
Know-how (as defined in Paragraph 1.4) related to the Products and methods,
these patents and pending applications listed in the attached Schedule 1.5, and
Licensor is willing to license such patents, pending applications and Know-how
to Licensee exclusively and in accordance with the terms of this Agreement;

         WHEREAS, Licensor has also developed certain trademarks related to the
Products and owns certain trademark registrations and pending trademark
applications as listed in the attached Schedule 1.6, and Licensor is willing to
license such trademarks including the trademark registrations and pending
applications in accordance with the terms of the Trademark License Agreement
attached hereto as Exhibit A;

         WHEREAS, Licensee desires to obtain an exclusive, worldwide,
royalty-bearing license from Licensor under all of those certain patents, patent
applications, Know-how, Product Improvements (as defined in Paragraph 1.3),
trademarks, and trademark applications relating to the development, manufacture,
sale and use of the Products and Licensed Methods (as defined in Paragraph 1.2).

         NOW, THEREFORE, in consideration of these premises, and the mutual
covenants and agreements hereinafter set forth and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties agree as follows:

         1. GENERAL DEFINITIONS. As used herein, the following terms shall be
defined in the manner set forth below:

         1.1 Products. The term "Products" shall mean the nasal support devices
for animals and parts and components thereof and related thereto and any other
products similar in function and purpose developed by Licensor or any of its
employees, consultants, agents or representatives prior to or during the term of
this Agreement based upon or using the Know-how or any claim within Patent
Rights. The term Products also specifically includes any product that is made by
a Licensed Method or is intended to be used in accordance with a Licensed
Method.

         1.2 Licensed Methods. The term "Licensed Methods" shall mean any
methods or techniques developed by Licensor of making or using the nasal support
devices for animals and parts and components thereof and related thereto and any
other products similar in function and purpose developed by Licensor or any of
its employees, consultants, agents or representatives prior to or during the
term of this Agreement based upon or using the Know-how or any claim within the
Patent Rights.

         1.3 Product Improvements. The term "Product Improvements" shall mean
any improvement or enhancement to the Products or any similar product conceived
of by Licensor or any of its officers, employees, consultants, agents or
representatives after the effective date of this Agreement which utilize any of
the Know-how, Patent Rights or Licensed Methods.

<PAGE>

         1.4 Know-how. The term "Know-how" shall mean any and all of the
information of any description directly relating to the Products and Licensed
Methods developed by or for Licensor at any time prior to or after the effective
date of this Agreement and connected or associated with the Patent Rights,
including, but not limited to, any and all tangible and intangible information,
technology, documents and materials in the possession and control of Licensor
(prior to the term of this Agreement), necessary or desirable in order to enable
Licensee to utilize fully the rights granted by Licensor to Licensee hereunder
and shall include, without limiting the foregoing, the ideas, concepts,
confidential information, trade secrets and techniques, as well as all the
materials, documents, manuals, schematics, blueprints, specifications, patterns,
art work, bills of materials and technical specifications and other information
owned or controlled by Licensor relating to the Products, Patent Rights and
Licensed Methods.

         1.5 Patent Rights. The term "Patent Rights" shall mean the following:
(i) the United States and foreign patent(s) and patent application(s) listed on
the attached Schedule 1.5 relating to the Products and Licensed Methods; (ii)
all future United States or foreign patent applications related to the Products,
Product Improvements and Licensed Methods and any patents arising therefrom;
(iii) the rights, patents and patent applications, if any, in any country or
jurisdiction in the world corresponding to the United States patents or patent
applications; and (iv) any division, continuation, continuation-in-part,
divisional, re-examined, reissued or extended letters patent, applications and
petty patents, utility models, utility model conversions, inventor's
certificates relating to the inventions claimed in any of the foregoing United
States patents and patents pending and foreign patent rights, which may be
developed, acquired or controlled by Licensor during the term of this Agreement
and with respect to which Licensor has or shall have the right to grant the
license hereinafter provided.

         1.6 Trademark Rights. The term "Trademark Rights" shall mean those
trademarks procured by Licensor and listed on the attached Schedule 1.6 for use
in connection with Products and Licensed Methods, including all current and
future registrations and pending trademark applications in the United States and
foreign countries that are related to those trademarks listed in Schedule 1.6.
The term Trademark Rights also includes any new trademarks that may be developed
by Licensor for application to the Products or the Licensed Methods.

         1.7 Contract Year and Quarter. The term "Contract Year" shall mean each
period of twelve (12) consecutive months commencing on the first day of the
first month of the Contract Quarter following the date Licensee elects, in its
sole discretion, to commercially introduce the Products (the "Product Acceptance
Date"); provided, however, the Product Acceptance Date shall in no event be
later than September 1, 1999 unless otherwise agreed by both parties. The term
"Contract Quarter" shall mean each period of three (3) consecutive months
commencing on the first day of (i) July, 1999 in the event that the Product
Acceptance Date occurs on or before August 15, 1999; or (ii) October, 1999 in
the event that the Product Acceptance Date occurs after August 15, 1999.

         1.8 Net Sales The term "Net Sales" shall mean the total amount
collected by Licensee or any sublicensee for sales of the Products to third
parties after a deduction of any: (i) sales, use or excise taxes; (ii) freight
or shipping charges; (iii) duty or insurance included therein; (iv) credits or
prepayments due to rejections; (v) defects or returns; and (vi) amounts for
trade and quantity discounts actually allowed and taken.

         1.9 Earned Royalty. The term "Earned Royalty" shall mean the royalty
payable to Licensor on the Net Sales from the sale of the Products.

         2. LICENSING AND COMMERCIALIZATION.

         2.1 Patent Rights and Know-how License. Licensor hereby grants to
Licensee a sole and exclusive, worldwide, royalty-bearing license, subject to
Paragraph 2.3 below, to manufacture, have others manufacture for it, use, sell,
distribute, export, or otherwise dispose of the Products and to practice the
Licensed Methods to make or use the Products under the Patent Rights and the
Know-how of Licensor.

<PAGE>

         2.2 Confidentiality of Know-how. Except as required by law or by a
governmental agency or as may otherwise be necessary or desirable for Licensee
to fully utilize the rights granted under this Agreement, Licensee agrees that
it will not, directly or indirectly, disseminate, disclose or otherwise make
available to any third party Know-how without the prior consent of Licensor and
will take all steps reasonably necessary to carry out this obligation so long as
Licensor has a reversionary right to such Know- how by the terms of this
Agreement, or unless such Know-how is already known to Licensee or until such
Know-how is, or becomes, generally known to the public or is subsequently
received by Licensee in good faith and without any restrictions as to disclosure
from a third party which has the right to make such disclosure. Notwithstanding
the foregoing, Licensee may disclose any Know-how to its directors, officers,
employees, representatives and agents who may need to know such information.

         2.3 Sublicenses. Except as may be otherwise necessary or desirable to
manufacture or have manufactured the Products or any components therefore,
Licensee may not sublicense to any third party, including affiliates of
Licensee, any rights granted by Licensor to Licensee hereunder in the United
States. Licensee may, however, sublicense any such rights to a third party or
affiliates outside the United States for selling the Products outside the United
States and without the right to import the Products into the United States. In
the event of any sublicense granted under this Paragraph 2.3, Licensee shall (1)
retain all rights and be responsible for all obligations under this Agreement,
and (2) enter into a written agreement with any such sublicensee (x) with a term
no greater than the term of this Agreement, (y) with rights granted to any such
sublicensee which are no greater than the terms of this Agreement, and (z)
pursuant to which Licensee shall use reasonable business efforts to impose upon
such sublicensees similar obligations as Licensor has imposed upon Licensee
under this Agreement.

         2.4 Assignments. Licensee may assign, convey or transfer any and all of
its rights under this Agreement ("Transfer") to a successor in interest of
substantially all of the assets or capital stock of Licensee (the "Acquirer").
In the event of such a Transfer, any such Acquirer shall assume all of the
obligations of Licensee hereunder and this Agreement shall be binding upon and
inure to the benefit of such Acquirer. Except as otherwise set forth in or
contemplated by Paragraph 2.3 above, no other Transfer may be made by Licensee
or the Acquirer unless Licensee or the Acquirer grants Licensor an exclusive
right of first refusal to purchase all of the rights conferred under this
Agreement in accordance with the following procedure:

         (a)      First, Licensee or the Acquirer, as the case may be, shall
                  give Licensor written notification of its intention to enter
                  into a transaction which operates to effectuate a Transfer (a
                  "Transaction") and shall not enter into any such Transaction
                  without first disclosing all material information about the
                  proposed Transaction to Licensor and offering to enter into a
                  Transaction on substantially identical terms with Licensor;
                  and then

         (b)      Second, Licensor shall, unless otherwise waived in writing by
                  Licensor, have a period of thirty (30) days after receipt of
                  written notification of any proposed Transaction to exercise
                  its right of first refusal and enter into a Transaction on
                  substantially identical terms. The right of first refusal
                  procedure outlined in this Paragraph 2.4 shall be repeated
                  prior to entering into by Licensee or the Acquirer of any
                  Transaction that is (a) on terms less favorable in a material
                  respect to the Licensee or the Acquirer than specified in an
                  earlier written notice to Licensor, or (b) with a party other
                  than that specified in an earlier written notice.

         2.5 Option for Product Improvements. Licensor shall own all of its
Product Improvements. Upon Licensor's conception and reduction to practice of
any Product Improvement, Licensor will disclose such Product Improvement to
Licensee in writing within a reasonable period of time, and subsequently,
Licensee shall have the first option to include any such Product Improvement
within the exclusive license granted above in Paragraph 2.1. Licensee shall make
its election under this option within thirty (30) days after disclosure from
Licensor.

         2.6 Patent Procurement and Costs. Licensee shall be solely responsible
for and pay all patent costs and expenses (including reasonable attorneys' fees)
to be incurred during the term of this Agreement in obtaining, prosecuting, and
maintaining any of the Patent Rights issued or to be issued under the law of any
country or jurisdiction identified on Schedule 2.6, including filing,
prosecution, working and maintenance costs and taxes. Notwithstanding the above,
Licensor shall direct and control the procurement and maintenance of the Patent
Rights and shall select patent counsel for such procurement or maintenance
(which counsel is subject to the reasonable consent of Licensee); provided,
however, that Licensee shall have

<PAGE>

the right to terminate such patent counsel if Licensee has a reasonable basis
for not being satisfied with such counsel's efforts or results, and in such
event Licensee shall select a new patent counsel (which counsel is subject to
the reasonable consent of Licensor). With respect to the procurement and
maintenance of any of the Patent Rights in countries not identified on Schedule
2.6, Licensor shall not be responsible for or required to pay any patent costs
or expenses unless it has given its prior written consent to the procurement of
such Patent Rights in any such country.

         2.7 Trademark Licensing. The Trademark Rights are licensed pursuant to
the "Trademark License Agreement" that is attached to this Agreement as Exhibit
A and made a part hereof.

         3. REPRESENTATIONS AND WARRANTIES.

         3.1 Licensor hereby warrants and represents to Licensee as follows:

                  (a) Licensor is a limited liability company duly organized,
         validly existing and in good standing under the laws of the State of
         Minnesota.

                  (b) This Agreement has been duly authorized, executed and
         delivered by Licensor and constitutes a valid and binding obligation of
         Licensor, enforceable in accordance with its terms, except as rights to
         indemnification thereunder may be limited by applicable law and except
         as and to the extent that the enforcement thereof may be limited by
         bankruptcy, insolvency, reorganization, moratorium or other similar
         laws relating to or affecting creditors' rights generally or by general
         equitable principles. The execution, delivery and performance of this
         Agreement and the agreements attached hereto by Licensor and the
         consummation of the transactions contemplated thereby have been
         authorized by all necessary corporate action and do not and will not
         conflict with or result in any material breach of any of the provisions
         of, or constitute a material default under, or result in a material
         violation of, or require any authorization, consent or approval, under
         the provisions of any organizational charter, articles, bylaw, member
         control, operating or other agreement, contract or instrument to which
         Licensor is bound or affected, or any law, statute, rule, regulation,
         judgment order or decree to which Licensor is subject.

                  (c) Licensor is the sole and exclusive owner of all the rights
         of James R. Chiapetta, Edward L. Blach and all other employees, agents,
         consultants or representatives of Licensor with respect to the
         Products, Licensed Methods, Patent Rights, Know-how and Trademark
         Rights.

                  (d) Licensor has been allowed and the issue fee has been paid
         for the United States patent(s) as listed on Schedule 1.5 covering the
         Products or Licensed Methods. Additional United States and
         international patent applications that are directed to the Products and
         Licensed Methods are currently pending as set forth on Schedule 1.5.
         Licensor has no knowledge of information that would render any of the
         listed patent applications (or patents granted therefrom) invalid or
         unenforceable.

                  (e) Licensor has good and marketable title to the Trademark
         Rights, Patent Rights and Know-how, free and clear of any and all
         liens, pledges, claims, licenses, assignments, conditional sales
         contracts, agreements or encumbrances of any kind that would impair
         Licensor's ability to grant the licenses under this Agreement or the
         Trademark License Agreement.

                  (f) Licensor has no knowledge that any of the Trademark
         Rights, Products, Licensed Methods, Patent Right or Know-how infringes
         on any patent, copyright, trademark, trade secret, trade dress or any
         other intellectual property right of any third party.

                  (g) None of Licensor's undertakings or activities in
         connection with the development, manufacture and sale of the Products
         involve the wrongful use of the proprietary rights or assets of any
         third party or give rise to any claim by any third party of ownership
         or rights in the Trademark Rights, Patent Rights, Licensed Methods or
         Know-how.

<PAGE>

                  (h) Licensor has not received notice of any claims, actions,
         suits or proceedings pending or threatened effecting Licensor, the
         Trademark Rights, the Patent Rights, the Licensed Methods or the
         Know-how, which, if adversely determined, would have a material adverse
         effect upon Licensee's ability to manufacture, have manufactured, use
         or sell the Products or otherwise practice the rights and technology
         licensed to Licensee by Licensor under this Agreement and, to
         Licensor's knowledge, there is no reasonable basis for anyone to bring
         such claims, actions, suits or proceedings.

                  (i) Licensor has not received any claim from any third-party
         proceedings relating to the Trademark Rights, Licensed Methods, Patent
         Rights or Know-how, or that the Products are based upon infringement of
         any patent or misappropriation or misuse of trade secrets or any other
         intellectual property right.

         3.2 Licensee hereby warrants and represents to Licensor as follows:

                  (a) Licensee is a corporation duly organized, validly existing
         and in good standing under the laws of the State of Delaware.

                  (b) This Agreement has been duly authorized, executed and
         delivered by Licensee and constitutes a valid and binding obligation of
         Licensee, enforceable in accordance with its terms, except as rights to
         indemnification thereunder may be limited by applicable law and except
         as the enforcement thereof may be limited by bankruptcy, insolvency,
         reorganization, moratorium or other similar laws relating to or
         affecting creditors' rights generally or by general equitable
         principles. The execution, delivery and performance of this Agreement
         and the agreements attached hereto by Licensee and the consummation of
         the transactions contemplated thereby do not and will not conflict with
         or result in any material breach of any of the provisions of, or
         constitute a material default under, or result in a material violation
         of, or require any authorization, consent or approval, under the
         provisions of Licensee's Certificate of Incorporation or Bylaws or
         other agreement, contract or instrument to which Licensee is bound or
         affected, or any law, statute, rule, regulation, judgment order or
         decree to which Licensee is subject.

         4. PAYMENTS, ROYALTIES AND REPORTS.

         4.1 Initial License Fee. On the date hereof, Licensee will pay to
Licensor the sum of $[CONFIDENTIAL TREATMENT REQUESTED] as an initial license
fee.

         4.2 Additional License Fees. Unless this Agreement is earlier
terminated or notice of termination is furnished in accordance with Paragraph
7.3 hereof, Licensee will pay to Licensor additional license fees in accordance
with the following:

                  (a) the sum of $[CONFIDENTIAL TREATMENT REQUESTED] on the
         Product Acceptance Date;

                  (b) the sum of $[CONFIDENTIAL TREATMENT REQUESTED] on the
         earlier of: (i) six (6) months after the Product Acceptance Date; or
         (ii) Net Sales from the sales of Products equal or exceed
         $[CONFIDENTIAL TREATMENT REQUESTED] in the aggregate; and

                  (c) the sum of $[CONFIDENTIAL TREATMENT REQUESTED] on the
         earlier of: (i) twelve (12) months after the Product Acceptance Date;
         or (ii) aggregate Net Sales from the sales of Products equal or exceed
         $[CONFIDENTIAL TREATMENT REQUESTED] U.S. in the aggregate.

         4.3 Royalties on Account of Net Sales.

                  (a) Licensee agrees to pay to Licensor royalties as follows
         based on the annual Net Sales from the sale of Products which are
         manufactured, used, sold or imported into a jurisdiction in which
         Licensor owns or controls an unexpired granted patent of Patent Rights
         containing a valid claim covering such manufacture, use, sale or
         importation: (a) [CONFIDENTIAL TREATMENT REQUESTED]% of Net Sales until
         royalties have been paid on a total of $[CONFIDENTIAL TREATMENT
         REQUESTED] U.S., then (b) [CONFIDENTIAL TREATMENT REQUESTED]% of Net
         Sales until royalties have been paid on a total of $[CONFIDENTIAL
         TREATMENT REQUESTED] U.S., then (c) [CONFIDENTIAL TREATMENT REQUESTED]%
         of Net Sales until royalties have been paid on a total of
         $[CONFIDENTIAL TREATMENT REQUESTED] U.S., and then (d) [CONFIDENTIAL
         TREATMENT REQUESTED]% of all Net Sales in excess of a total of
         $[CONFIDENTIAL TREATMENT REQUESTED] U.S.

<PAGE>

                  (b) The royalty percentages provided for in Paragraph 4.3(a)
         above shall be reduced by [CONFIDENTIAL TREATMENT REQUESTED]
         ([CONFIDENTIAL TREATMENT REQUESTED]) on account of Net Sales of
         Products which are manufactured, used, sold or imported into a
         jurisdiction in which Licensor does not own or control an unexpired
         granted patent of Patent Rights containing a valid claim covering such
         manufacture, use, sale or importation.

                  (c) In the event that any third party sells or markets a nasal
         support device that competes with the Products in a particular
         jurisdiction and Licensee is unable to prohibit such competitor from
         marketing or selling such a competitive product in the particular
         jurisdiction through patent proceedings or other measures set forth in
         or contemplated by Section 6, the royalties provided for hereunder
         shall be proportionately reduced such that the royalty percentages then
         in effect under either Paragraphs 4.3(a) and 4.3(b) above shall be
         multiplied by the market share held by Licensee in the particular
         jurisdiction as determined by Licensee every six (6) months in a good
         faith analysis of the relevant markets and the competitive effect of
         such products on Net Sales.

                  (d) It is further understood and agreed by the parties that a
         Product sold and subject to royalty under this Agreement shall not be
         subject to more than one royalty payment and that the royalties
         provided for under this Agreement shall in no event be reduced to less
         than [CONFIDENTIAL TREATMENT REQUESTED]% of Net Sales.

         4.4 Quarterly Payments. All royalties due Licensor from Licensee
hereunder shall be payable on a Contract Quarterly basis. Within thirty (30)
days after the end of each Contract Quarter during the term of this Agreement,
Licensee shall pay to Licensor the royalty due Licensor under Paragraph 4.3
through the end of the preceding Contract Quarter and shall furnish Licensor
with a written statement setting forth the number of Products sold and the Net
Sales received during such Contract Quarter, and the resulting amount of the
royalty due Licensor under Paragraph 4.3.

         4.5 Minimum Royalties. To maintain its rights hereunder, Licensee shall
pay to Licensor minimum royalties after the Product Acceptance Date in
accordance with Paragraph 4.4 and the following:

<TABLE>
<CAPTION>
                      Minimum Royalty Payment                Minimum Royalty Payment
Contract Year*           Per Contract Year                     Per Contract Quarter
--------------           -----------------                     --------------------
<S>             <C>                                    <C>
Year 1          $[CONFIDENTIAL TREATMENT REQUESTED]    $[CONFIDENTIAL TREATMENT REQUESTED]
Year 2**         [CONFIDENTIAL TREATMENT REQUESTED]     [CONFIDENTIAL TREATMENT REQUESTED]
</TABLE>

*Twelve-month periods beginning on the Contract Year.

**Unless earlier terminated in accordance with Section 7 of this Agreement,
through the Contract Year of the expiration date of the last of the Patent
Rights.

         4.7 Minimum Royalty Payment. Licensee shall pay Licensor within thirty
(30) days after the end of each Contract Quarter, an amount equal to (i) the
minimum royalties payable pursuant to the terms of Paragraph 4.5 for the
Contract Quarter then ended, less (ii): (a) the aggregate amount of Earned
Royalties actually paid to Licensor pursuant to the terms of Paragraphs 4.3 and
4.4 for the Contract Quarter then ended; and (b) any Earned Royalties paid to
Licensor during the prior Contract Quarters in the current Contract Year that
exceed the amount of cumulative minimum royalties payable for those Contract
Quarters. Licensee's failure to pay any and all amounts payable under the
preceding sentence within thirty (30) days after receipt of written notice from
Licensor that such amounts have not been timely paid shall render the licenses
granted hereunder void and thereupon, Licensee shall have no further rights or
interests of any kind or nature with respect to the Products, Patent Rights and
Know-how, and Licensee shall take any and all action that Licensor may
reasonably request to further document the provisions hereof. In the event that
any law, statute, regulation, rule, guideline, ruling, order or decision
prevents Licensee from marketing or offering the Products for sale, the minimum
royalty payment will be suspended until such time that Licensee is no longer
prevented from marketing or offering the Products for sale.

<PAGE>

         4.8 Late Payment. Licensee shall pay a late payment fee to Licensor for
any Contract Quarter when the royalty amount that is due and payable is not made
within thirty (30) days after the end of that Contract Quarter. The late payment
fee shall be calculated at a variable rate of two percent (2%) over the prime
per annum interest rate as set from time to time by Norwest Bank Minneapolis,
N.A., Minneapolis, Minnesota (the "Interest Rate"), on any and all amounts that
are at any time overdue and payable to Licensor under this Agreement, such
interest being calculated on each such overdue amount from the date when such
amount became due to the date of actual payment thereof. Such late payment fee
shall be in addition to and not in lieu of any and all other rights or remedies
that Licensor may have under this Agreement or law relating to a default by
Licensee under this Agreement.

         4.9 Records. During the term of this Agreement and for three (3) years
after termination of this Agreement, Licensee shall at all times maintain
accurate and up-to-date records containing complete data from which amounts due
to Licensor under this Agreement may be readily calculated. Further, Licensee
shall preserve and permit examination of such records by Licensor's
representatives or independent auditors at reasonable intervals and under
reasonable conditions during the term of this Agreement and for three (3) years
thereafter and, upon request, shall supply to Licensor's representatives or
independent auditors all information reasonably requested that is useful in
making a proper audit and verification of Licensee's performance of its
obligations under this Agreement and of any sublicensee's performance in
accordance with the terms of this Agreement.

         4.10 Underpayment. If Licensor determines by audit and inspection of
Licensee's books and records that Licensee has failed to pay all royalties due
under Paragraph 4.4, Licensee shall pay Licensor one hundred five percent (105%)
of such additional royalties as may be due in addition to the interest as
provided for in Paragraph 4.8 above. If the amount of underpayment exceeds 5% of
the royalties due under Paragraph 4.4, then Licensor shall, in addition to any
other remedies available to it, recover from Licensee the reasonable costs
incurred in making any such audit and inspection pursuant to Paragraph 4.9
hereof which revealed such shortfall.

         5. INDEMNIFICATION.

         5.1 Indemnification by Licensor. Licensor shall defend, indemnify and
hold Licensee and its shareholders, directors, officers, agents,
representatives, successors and assigns harmless from and against any and all
claims, damages, costs (including reasonable attorneys' fees), judgments, fines,
penalties, losses, diminution in value and liabilities of any kind or nature:
(a) arising out of the breach by Licensor of any of its warranties,
representations and covenants under this Agreement or the Trademark License
Agreement; (b) arising out of any misuse by Licensor of the patent process or
fraud by Licensor on the patent office.

         5.2 Indemnification by Licensee. Licensee shall defend, indemnify and
hold Licensor and its shareholders, directors, officers, agents,
representatives, successors and assigns harmless from and against any and all
claims, damages, costs (including reasonable attorneys' fees), judgments, fines,
penalties, losses, diminution in value and liabilities of any kind or nature
arising out of any act of Licensee including, but not limited to, those: (a)
arising out of the breach by Licensee of any of its warranties, representations
and covenants under this Agreement or the Trademark License Agreement; or (b)
arising out of any actual or alleged defect in a Product.

         6. PROTECTION AGAINST INFRINGEMENT. In the event that Licensee becomes
aware of activity on the part of any third party which may constitute
infringement of the Patent Rights, or any other intellectual property rights
with respect to which Licensee is granted a license hereunder, Licensee shall
give Licensor written notice thereof. Licensee shall, at its sole discretion and
expense, have the first exclusive right to initiate and thereafter maintain
reasonable efforts to prevent and abate such infringement, including the
initiation of an appropriate civil action for infringement and the taking of
such other action as may determine to be necessary or appropriate to enforce the
Patent Rights or other intellectual property rights with respect to which
Licensee is granted a license hereunder. In such event, (i) Licensor will permit
the use of its name in, and as a party to, all such suits and execute all
pleadings, documents and other papers necessary or appropriate in conjunction
therewith, and (ii) Licensee shall receive the full benefits of any action it
takes pursuant to this Paragraph, including retaining all sums recovered in any
such suit or in settlement thereof after paying Licensor the Earned Royalties
which shall be calculated from the amount of Net Sales, if any, asserted by
Licensee to support any award of compensatory damages (as opposed to

<PAGE>

punitive or any other damages). In the event that Licensee fails or refuses to
take or cause to be taken any such measures against any third party after six
(6) months from the date of receipt of written notice to Licensee by Licensor of
such infringement, Licensor may take such legal action in its own name or in the
name of Licensee (if needed) and at its own expense upon giving fourteen (14)
days advance, written notice of its intention to do so. In this case, all
damages recovered as a result of such action by Licensor shall be and become the
property of Licensor. If either party litigates under this Section 6, the other
party may, at its option and its cost and expense, participate in meetings with
the litigating party and/or its counsel and receive all pleadings, documents and
other related papers useful for the purpose of keeping the other party informed
of the status of any proceedings commenced by the litigating party.

         7. TERM AND TERMINATION.

         7.1 Term. This Agreement and the Trademark License Agreement shall
commence on the effective date hereof and shall expire, unless earlier
terminated pursuant to Paragraphs 7.2 or 7.3 of this Agreement, upon the
expiration of the last of the Licensed Patents to expire.

         7.2 Termination by Licensor. If Licensee is in material default of any
of its obligations under this Agreement, Licensor shall have the right to
terminate this Agreement by giving thirty (30) days' written notice of
termination specifying the reason for termination, provided that such notice
will be of no effect and termination will not occur if the specified default is
cured prior to the expiration of said thirty (30) day notice period.

         7.3 Termination by Licensee.

                  (a) This Agreement and the Trademark License Agreement may be
         terminated by Licensee at any time at will, with or without cause, by
         the giving of at least ninety (90) days' prior written notice to
         Licensor by Licensee in which event any license granted hereunder
         shall, except as otherwise set forth in or contemplated by Paragraph
         7.3(b) hereof, terminate upon the effective date of the termination
         (the "Termination Date") stated in any such notice. In the event of the
         termination of any such license, neither Licensor nor Licensee shall
         have any further obligation to the other party hereunder except as
         expressly provided in Paragraphs 7.3(b), 7.3(c) or 7.4 of this
         Agreement below.

                  (b) Upon termination of any license granted hereunder or under
         the Trademark License Agreement, Licensee may, after the effective date
         of such termination, sell any of its (i) completed Products, (ii)
         Products then in the process of manufacture, and (iii) Products with
         respect to which manufacture has been committed at the time of
         termination by reason of either (x) any contracts for the purchase of
         materials to be used in the manufacture of such Products or (y) any
         contract for the sale of such Products, and may, in its sole
         discretion, utilize any of the rights granted by Licensor under the
         Trademark License Agreement. All such sales and uses shall be subject
         to the royalty provisions of Section 4 of this Agreement as though the
         termination of this Agreement had not occurred.

                  (c) Except as expressly provided in Paragraph 7.3(b), after
         termination of this Agreement, Licensee may not use develop, market or
         sell the Products, Product Improvements, Licensed Methods, Patent
         Rights and Know-how, in any way or manner that would violate any rights
         of Licensor and Licensee shall take any and all steps reasonably
         requested by Licensor to completely vest all rights licensed hereunder
         to Licensee back to Licensor upon any such termination. Furthermore,
         Licensee may not use any trademark of the Trademark Rights, and all
         Trademark Rights shall remain the property of Licensor or will
         thereafter be assigned to Licensor. Termination of this Agreement shall
         operate to terminate the Trademark License Agreement.

                  (d) In the event that Licensee terminates this Agreement and
         the Trademark License Agreement under this Section 7, Licensee shall,
         upon written request of Licensor, deliver to Licensor copies of all
         material scientific and marketing research documentation related to or
         used in connection with the Products including, but not limited to,
         manufacturing sources and technical specifications, reports, surveys,
         know-how, trademarks (except the Breathe Right(R) trademark), customer
         lists and other information prepared for or by Licensee with respect to
         which Licensee shall have the right to deliver; provided, however, that
         the delivery of any such information and materials will not impair any
         trade secret relating to Licensee's other existing or contemplated
         products or be deemed by Licensee to be otherwise confidential in
         nature.

<PAGE>

                  (e) In the event that Licensee terminates this Agreement under
         this Section 7, Licensee shall grant to Licensor a limited,
         non-exclusive, worldwide, non-royalty bearing license to any and all
         improvements to the Products developed by Licensee or any of its
         employees or consultants between the date hereof and Termination Date
         which Licensee shall have the right to grant; provided, however, that
         (i) nothing contained in this Paragraph 7(e) shall be in any way
         construed to confer upon Licensor or any third party any rights to such
         improvements which may be subject to the proprietary protection of a
         party other than Licensee including, without limitation, the rights
         granted to Licensee by Creative Integration & Design, Inc. and its
         affiliates; (ii) the license granted shall be applicable to the
         Products and limited for use in the area of nasal support devices for
         animals and no other purpose.

         7.4 Continued Obligations. Termination shall not relieve or release
either party from its obligations to make any payment which may be owing to the
other under the terms of this Agreement or from any other liability which either
party may have to the other arising out of the terms of this Agreement.
Additionally, notwithstanding anything contained herein to the contrary,
Sections 3, 5 and 9 shall survive termination of this Agreement and remain in
full force and effect.

         8. LICENSEE'S UNDERTAKINGS.

         8.1 Exploitation. Licensee hereby agrees that during the term of this
Agreement it will use its best efforts to manufacture, sell and market the
Products, and will exert its best efforts to create a demand for the Products in
appropriate worldwide markets, and to increase and extend its business in the
manufacture, sale and marketing of the Products in appropriate worldwide
markets.

         8.2 Distribution. Licensee agrees to undertake and will use its best
efforts to investigate and, if determined by Licensee to be commercially
feasible, develop a direct distribution system whereby the Products may be
marketed directly to the end user.

         8.3 Marking. Licensee agrees to apply appropriate patent notices to the
Products and to any product advertisements and packaging.

         8.4 Additional Consent or License. In the event that Licensee believes
it to be necessary or desirable to obtain the consent or a license from Creative
Integration & Design, Inc. to practice some or all of the Patent Rights under
this Agreement, the fees paid by Licensee for any such consent or license shall
not affect the royalties set forth in this Agreement. In addition, Licensor
acknowledges and agrees that any and all of the rights granted to Licensee by
Creative Integration & Design, Inc. are not in any way intended to be considered
transferrable or impaired hereunder any circumstances.

         9. MISCELLANEOUS.

         9.1 Recitals, Schedules and Exhibits Incorporated. The Recitals,
Schedules and Exhibits are true and correct, incorporated herein and made a part
of this Agreement as specifically set forth.

         9.2 Force Majeure. Neither party shall be responsible for any delay or
failure in the performance of any obligation hereunder due to strikes, lockouts,
fires, floods, acts of God, embargoes, wars, riots, or act or order of any
government or governmental agency; provided, however, nothing set forth in this
Paragraph 9.2 (except as otherwise set forth in or contemplated by Paragraph 4.7
of this Agreement) shall be construed to relieve Licensee of the requirement
that it pay minimum royalties pursuant to Paragraphs 4.5 hereof.

         9.3 Waiver. The waiver or failure of either party to enforce the terms
of this Agreement in one instance shall not constitute a waiver of said party's
right under this Agreement with respect to other violations.

<PAGE>

         9.4 Remedies. The election by either party of any particular right or
remedy shall not be deemed to exclude any other right or remedy and all rights
and remedies of either party shall be cumulative. The parties agree that, in
addition to any other relief afforded under the terms of this Agreement or by
law, each party shall have the right to enforce this Agreement by injunctive or
mandatory relief to be issued against the other party, it being understood that
both damages and specific performance shall be proper modes of relief and are
not to be considered as alternative remedies.

         9.5 Notices. All notices and replies thereto required hereunder shall
be in writing, signed by the party giving notice, placed in an envelope and
either delivered by hand or sent by facsimile or registered mail, postage
prepaid, return receipt requested, and properly addressed to the other party.
Notices sent by mail shall be deemed received on the date of receipt indicated
by the receipt verification provided by the United States Postal Service.
Notices sent by facsimile shall be deemed received on the date indicated on the
sender's confirmation report. Notice shall be given, mailed or sent to the other
party at the following addresses or at such other address as may be given by
proper notice:

         If to Licensor:     WinEase, LLC
                             [CONFIDENTIAL TREATMENT REQUESTED]
                             [CONFIDENTIAL TREATMENT REQUESTED]
                             Attn: James R. Chiapetta
                             Fax No.: [CONFIDENTIAL TREATMENT REQUESTED]

         If to Licensee:     CNS, Inc.
                             4400 West 78th Street
                             Minneapolis, MN 55435
                             Attn: Daniel E. Cohen, M.D.
                             Fax No.: (612) 820-6697

         With a copy to:     Lindquist & Vennum P.L.L.P.
                             4200 IDS Center
                             80 South 8th Street
                             Minneapolis, MN 55402-2205
                             Attn: Patrick Delaney
                             Fax No.: (612) 317-3207

         Either party hereto may designate any other address for notices given
hereunder by written notice to the other party given at least ten (10) days
prior to the effective date of such change.

         9.6 Entire Agreement. This Agreement, together with the attached
schedules and exhibits, represents the entire agreement between the parties with
respect to the subject matter hereof and supersedes all prior agreements and
discussions (whether written or oral); there are no oral promises,
representations or warranties not set forth in this Agreement. No modification
of this Agreement or waiver of any of its terms shall be binding upon the
parties unless said modification or waiver is in writing, signed by both
parties, and states that it is an amendment to this Agreement.

         9.7 Parties in Interest. This Agreement shall inure to the benefit of,
be binding upon, and be enforceable against the parties hereto, their respective
successors and assigns.

         9.8 Governing Law. The parties hereby irrevocably submit and consent to
the jurisdiction of Minnesota state and federal courts over any action or
proceeding arising out of or relating to this Agreement and further agree that
all claims in respect of such action or proceeding shall be heard and determined
in any such court which shall construe and enforce the Agreement under the
internal laws (and not the laws of conflicts) in such state. Licensor and
Licensee hereby waive any argument that venue in such forums is not convenient.

<PAGE>

         9.9 Severability. If any portion of this Agreement is held invalid by
the final judgment of any court of competent jurisdiction, such portion shall be
deemed revised or "blue lined" so that it is enforceable to the fullest extent
possible under applicable law and the remaining provisions shall remain in full
force and effect as if such invalid provision had not been included herein.

         9.10 Reasonableness. Licensor and Licensee agree that the restrictions,
covenants, agreements and obligations contained in this Agreement are reasonable
and necessary to protect the legitimate interests of the parties.

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.

                                       CNS, INC.

                                       By:
                                          --------------------------------------
                                          Its:
                                               ---------------------------------

                                       WINEASE, LLC

                                       By:
                                          --------------------------------------
                                          Its:
                                               ---------------------------------

<PAGE>

                                LIST OF SCHEDULES

                   Number                            Description
                   ------                            -----------

                   1.5                               Patent Rights
                   1.6                               Trademark Rights
                   2.6                               Countries List

<PAGE>

                                  SCHEDULE 1.5

                         DESCRIPTION OF LICENSED PATENTS

         U.S. Patent Applications and all other applications and continuations
thereof filed in connection with the Products together with any and all
international filings as further described in Section 1.3 of this Agreement.

                  Application                                     Status
                  -----------                                     ------

         U.S. patent application serial no. 08/843,741    Issue fee paid 12/3/98

         U.S. patent application serial no. 09/018,603    Filed 2/4/99

         U.S. patent application serial no. 09/250,658    Filed 2/16/99

         M&G docket no. 12460.1-US-I2                     Filed 3/8/99

         PCT/US98/07885                                   Filed 4/17/98

<PAGE>

                                  SCHEDULE 1.6

                     DESCRIPTION OF CERTAIN TRADEMARK RIGHTS

         U.S. trademark registration and pending trademark applications as
further described in Section 1.6 of this Agreement.

         FLAIR

         NSD

<PAGE>

                                  SCHEDULE 2.6

                                 COUNTRIES LIST

         1.    United States;

         2.    Canada;

         3.    China;

         4.    Japan;

         5.    Mexico;

         6.    New Zealand;

         7.    Australia; and

         8.    Countries located in Europe.

<PAGE>

                                    EXHIBIT A

                           TRADEMARK LICENSE AGREEMENT

         This Trademark License Agreement (the "Agreement") is entered into and
is effective as of this 12th day of March, 1999 by and between WinEase, L.L.C.
("LICENSOR"), a Minnesota limited liability company, and CNS, Inc. ("LICENSEE"),
a Delaware corporation, upon the following terms and conditions:

                                    Recitals

         WHEREAS, LICENSOR and LICENSEE have entered into that certain license
agreement on even date herewith (the "License Agreement");

         WHEREAS, LICENSOR is the sole and exclusive owner of the certain
"Trademark Rights" (as defined in the License Agreement); and

         WHEREAS, LICENSEE wishes to have the right but not the obligation use
the Trademark Rights in connection with the sale and marketing of the "Products"
(as defined in the License Agreement) and to license from LICENSOR whatever
rights LICENSOR may have in the Trademark Rights for use in connection with the
Products;

         WHEREAS, LICENSOR is willing to grant such a license on the terms and
conditions set forth in this Agreement;

         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are acknowledged by the parties hereto, LICENSOR and
LICENSEE agree as follows:

                              Terms and Conditions

         1. Definitions. The following definitions shall apply to this
Agreement:

                  1.1 The term "Marks" shall mean the Trademark Rights.

                  1.2 The term "Licensed Goods" shall mean the Products.

                  1.3 The term "Term" shall mean the time period specified in
paragraph 3 of this Agreement.

                  1.4 The term "Territory" shall mean worldwide.

         2. Grant of Rights and Licenses. Subject to all of the terms and
conditions of this Agreement, LICENSOR hereby grants to LICENSEE an exclusive,
worldwide, royalty-free right and license during the Term of this Agreement to
reproduce, display, broadcast, publish and otherwise use any of the Marks in
connection with the Licensed Goods by LICENSEE throughout the Territory, and
LICENSEE hereby accepts such right and license subject to the terms and
conditions of this Agreement. Notwithstanding anything contained in this
Agreement to the contrary, LICENSEE shall not be under any obligation to use any
of the Marks in connection with the sale of the Products or otherwise.

         3. Term. This Agreement and any licenses granted by LICENSOR hereunder
shall commence as of the effective date hereof and shall continue in full force
and effect through the term of the License Agreement, at which time they will
automatically terminate, unless sooner terminated in accordance with the terms
and conditions of the License Agreement.

<PAGE>

         4. Quality Assurance.

                  4.1 LICENSOR is familiar with LICENSEE'S human nasal dilator
products and finds them to be of acceptable quality. LICENSEE agrees that any of
the Licensed Goods used with the Marks will be of substantially similar quality.
LICENSEE agrees to submit evidence of the nature of the Licensed Goods used with
the Marks to LICENSOR for review and approval from time to time upon LICENSOR's
reasonable request.

                  4.2 LICENSEE agrees to take all responsibility for any
Licensed Goods with which the Marks are used. LICENSEE agrees to comply in all
material respects with all applicable laws and regulations and obtain all
appropriate governmental approvals pertaining to the Licensed Goods offered in
connection with the Marks.

         5. Trademark Use and Ownership.

                  5.1 In the event that LICENSEE shall at any time elect to use
any of the Marks, LICENSEE agrees to use the Marks only in the form and manner
with appropriate legends as may be prescribed from time to time by LICENSOR.

                  5.2 In the event that LICENSEE shall at any time elect to use
any of the Marks, LICENSEE agrees that it shall cause to appear in connection
with the Licensed Goods, such reasonable trademark notice as LICENSOR may
reasonably designate.

                  5.3 LICENSEE acknowledges and agrees that LICENSOR is the
owner of all rights in and to the Marks and that LICENSEE will not during the
Term of this Agreement or at any time thereafter use the Marks or any element
thereof in any form and for any goods or services or challenge the use or
registration thereof except as permitted under this Agreement or contemplated by
the License Agreement without the prior written permission of LICENSOR.

                  5.4 LICENSEE agrees that it will not state or imply either
directly or indirectly that LICENSEE or LICENSEE's activities, other than those
permitted by this Agreement, are supported, endorsed, or sponsored by LICENSOR
and, upon the direction of LICENSOR, LICENSEE.

                  5.5 LICENSEE recognizes the goodwill associated with the Marks
and acknowledges that said goodwill belongs exclusively to LICENSOR and that any
use of the Marks by LICENSEE at any time (whether during or after the term of
this Agreement) will, except as otherwise contemplated by the transactions set
forth in the License Agreement, inure solely to the benefit of LICENSOR, and
LICENSEE hereby assigns any such goodwill in its entirety to LICENSOR upon
termination of this Agreement. Nothing contained herein shall be construed to
confer upon LICENSOR any rights of LICENSEE in or to the Breathe Right(R) mark.

                  5.6 LICENSEE will comply with the provisions of all laws of
the United States and each state in which it elects, in its sole discretion, to
use the Marks regarding trademarks and service marks.

         6. Infringement. LICENSEE agrees to notify LICENSOR promptly of any
known use of the Mark by others not duly authorized by LICENSOR. Notification of
such infringement shall include all details known by LICENSEE that would enable
or aid LICENSOR to investigate such infringement.

         7. Disputes Relating to the Mark. The parties acknowledge and agree
that all of the provision of Paragraph 6 of the License Agreement shall govern
the parties' rights with respect to disputes relating to the Marks with third
parties.

<PAGE>

         8. No Agency. Nothing contained herein shall be deemed to create an
agency, joint venture, franchise, or partnership relationship between LICENSEE,
on the one hand, and LICENSOR, on the other hand, and no party shall so hold
itself out. LICENSEE shall have no right to obligate or bind LICENSOR in any
manner whatsoever.

         9. Limited Warranty.

                  9.1 LICENSOR warrants it has the lawful capacity to execute
this Agreement, but does not warrant and shall not be held to have warranted the
validity or scope of the Marks licensed under this Agreement except as may
otherwise be set forth in the License Agreement.

                  9.2 LICENSOR makes no representations or warranties with
respect to the Licensed Goods provided by LICENSEE and disclaims any liability
arising out of the Licensed Goods offered by LICENSEE under the Marks except as
may otherwise be set forth in the License Agreement.

         10. Assignability. This Agreement shall inure to the benefit of
LICENSOR, its successors and assigns, but will be personal to LICENSEE and shall
be assignable by LICENSEE only to the extent that the rights of LICENSEE are
assignable under the License Agreement.

         11. Termination. The termination of the License Agreement shall operate
to terminate this Agreement.

         12. Effect of Termination.

                  12.1 Except as may otherwise be set forth in Section 7 of the
License Agreement, the license granted hereunder shall cease immediately upon
termination of this Agreement for any reason.

                  12.2 The exercise by any party of its rights to terminate this
Agreement as provided herein shall be in addition to and not in lieu of any
other remedies such party may have under this Agreement or otherwise.

         13. Waiver. No waiver by a party of any breach of any term or provision
of this Agreement shall be construed to be a waiver of any preceding or
succeeding breach of the same or any other term or provision hereof. The
parties' various rights and remedies under this Agreement shall be construed to
be cumulative and no one of them is exclusive of any other or of any right or
remedy allowed by law or in equity.

         14. Notices. All notices to be given hereunder must be in writing and
shall be given hereto in the manner and at the addresses set forth in the
License Agreement.

         15. No Act Contrary to Law; Severability. Nothing contained in this
Agreement shall be construed to require the commission of any act contrary to
law and wherever there is any conflict between any provision of this Agreement
and any present or future statute, law, governmental regulation or order or
ordinance, then the latter shall prevail, and in such event the provision or
provisions of the Agreement affected shall be curtailed and limited only to the
extent necessary to bring it or them within legal requirements. All other terms
of the Agreement shall remain unaffected.

         16. Governing Law; Jurisdiction. This Agreement shall be deemed to have
been made in the State of Minnesota, and its validity, construction and effect
shall be governed by and enforced pursuant to the substantive laws of the State
of Minnesota without regard to its conflicts of laws principles.

<PAGE>

         17. Entire Agreement. This Agreement, together with the License
Agreement and attached schedules, constitutes the entire agreement between the
parties relating to the subject matter hereof and shall supersede any and all
prior written or oral agreements between the parties relating to the subject
matter hereof. This Agreement may not be amended except by a written instrument
signed by each of the parties hereto. Each party acknowledges that it has not
executed this Agreement in reliance upon any representation or promise made by
any person, except as expressly provided for in this Agreement or the License
Agreement.

         18. Inconsistent Provisions. To the extent that any term or provision
in this Agreement is inconsistent with any term or provision in the License
Agreement, the terms and provisions of the License Agreement shall in all
respects control.

         19. Unavoidable Delay. If any party's obligations hereunder are
affected by reason of fire, flood, casualty, Act of God, lockout, strike, labor
conditions, unavoidable accident, LICENSOR calamity, mechanical or other
breakdown, riot, enactment of law or by any similar cause (collectively referred
to as "Unavoidable Delay"), its obligations hereunder herein shall be suspended
during the period of such suspension period due to the Unavoidable Delay, except
that any such suspension period due to such Unavoidable Delay shall in no event
exceed six (6) months.

         20. Headings. The headings or captions of this Agreement or any
paragraph hereof are inserted for purposes of convenience only and shall not be
deemed to limit, affect the scope, meaning or intent of this Agreement, nor
shall they otherwise be given any legal effect.

         21. Recitals. The Recitals are true and correct, incorporated herein
and made a part of this Agreement.

         22. Counterparts. This Agreement may be executed in one or more
counterparts, each of which will be deemed an original and will, when taken
together, constitute this Agreement notwithstanding that each party is not a
signator to the same counterpart.

         23. Binding on Successors. This Agreement will fully bind and inure to
the benefit of each party and its respective heirs, successors, permissible
assigns, and agents.

         24. Further Documents. The parties agree to execute such further
documents as may be reasonably requested by the others to effectuate any of the
provisions or purposes of this Agreement.

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their authorized agents effective as of the date first written
above.

                                       LICENSOR:

                                       WinEase, LLC

                                       By
                                         ---------------------------------------
                                       Print Name:
                                                  ------------------------------
                                       Title:
                                             -----------------------------------

                                       LICENSEE:

                                       CNS, Inc.

                                       By
                                         ---------------------------------------
                                       Print Name:
                                                  ------------------------------
                                       Title:
                                             -----------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00005-of-00352.parquet"}]]